Regulatory14 Oct 2026 · Wed 6:23 AM
ZYDUSLIFEZydus Lifesciences
USFDA inspection of Zydus's Moraiya plant ends with five observations
The US drug regulator inspected Zydus Lifesciences' Moraiya formulation plant in Gujarat from 5 to 13 October and issued five observations.
Price, Tuesday's close₹1,132.50▼ 0.17%
52-week low ₹835.5052-week high ₹1,232.10
- Sector
- Pharma
What happened
- The inspection ran from 5 to 13 October and closed with five Form 483 observations, according to Sahi.
- Sahi said the company has committed to addressing all observations within statutory timelines.
- Zeebiz's round-up also listed the Moraiya inspection among the company's updates.
- The shares closed at ₹1,132.50 on Tuesday, down 0.17%, per Zerodha Kite.
Why it matters
Sahi describes the Moraiya site as important to Zydus's US formulations business; observations are the inspector's findings and are not a final regulatory classification.
Good to know: A Form 483 lists conditions an inspector believes may breach manufacturing rules. The company replies in writing, and the USFDA then decides how to classify the inspection.
Key facts
- Site
- Moraiya formulation plant, Gujarat
- Inspection dates
- 5 to 13 October
- Observations
- 5 (Form 483, per Sahi)
Read the source
This is a summary of public news about Zydus Lifesciences, for information only. It is not a recommendation to buy, sell or hold ZYDUSLIFE.
Zydus Lifesciences in the news before
- 29 SEP 2026 · EVENING · REGULATORYUSFDA records one observation at Zydus's Ahmedabad SEZ II plant